FTD SARS-CoV-2 Assay1
For the specific detection of the novel coronavirus causing COVID-19
Respiratory Testing
In late 2019, China notified the World Health Organization (WHO) of a novel strain of coronavirus. This virus, now named SARS-CoV-2, targets the epithelial cells of the respiratory tract and causes infection that can lead to Coronavirus disease 2019 (COVID-19). Siemens Healthineers new molecular assay uses real-time PCR to detect RNA from this virus.
Features & Benefits
- Kit comprised of a single-well dual target assay for the specific detection of SARS-CoV-2 (COVID-19)
- Designed for high sensitivity, specificity, and inclusivity
- Covers highly conserved regions within ORF1ab and N gene
- Uses the same assay setup protocol and thermal-cycling profile as all FTD respiratory disease kits2
Assays
Share this page:
Because of some maintenance activities, this service is not available currently.
Please try again later.
Your information has been submitted.
If you requested more information, a representative will contact you shortly.
To keep up to date with Siemens Healthineers news and events specific to your interest area, sign up for Siemens Healthineers eNews and choose your individualized preferences.
Due to technical reasons your request cannot be completed. Please try again or contact us. We apologize for the inconvenience caused.
Related Products, Services & Resources
Product availability varies by country and is subject to local regulatory requirements.
1CE-IVD labelled for diagnostic use in the EU. Pursuing WHO emergency use listing (EUL). This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21. U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
2CE-IVD labelled for diagnostic use in the EU. For research use only (RUO) in the U.S.